Press Releases

Published On 13 April

IVQ launches Personalised Cancer Screening Service Onco-PDO

Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™

Learn more
Published On 26 February

Grant from Northern Ireland to commercialize Onco-PDO

Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO

Learn more
Published On 18 January

IVQ successfully grows liver cancer organoids

Invitrocue further validates its Onco-PDO technology platform through the successful growth of 14 liver cancer organoids

Learn more
Published On 29 August

IVQ receives award from Singapore government IP office

IVQ receives award from Singapore government IP office

Learn more
Published On 24 July

Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment

L-R: Dr Benjamin Seet, Executive Director of the Biomedical Research Council, A*STAR; His Excellency Bruce Gosper, the Australian High Commissioner to Singapore; Dr Steven Fang, Chief Executive Officer / Founder, Invitrocue Ltd; The Hon Martin Hamilton Smith, Minister for Trade and Investment, South Australian Government; Dr Raj Thampuran, Managing Director, A*STAR; Professor Ng Huck Hui, […]

Learn more
Published On 03 July

Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs

July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of […]

Learn more
Published On 22 May

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma […]

Learn more
Published On 23 February

Invitrocue Signs Research Collaboration Agreement with the Garvan Institute of Medical Research

February 23, 2017 – Invitrocue (ASX: IVQ) is pleased to announce that the company has signed a Collaborative Research Master Agreement with the Garvan Institute of Medical Research. The aim of the collaboration is to provide further medical validation of Invitrocue’s technology for use in personalised real time screening of cancer drugs. It is envisaged […]

Learn more
Published On 24 October

Invitrocue Signs Research Collaboration Agreement with Genome Institute of Singapore for Colorectal Cancer Organoids

October 24, 2016 – Invitrocue (ASX:IVQ) announced a collaboration agreement with the  Cancer Therapeutics and Stratified Oncology Group at the Genome Institute of Singapore (GIS), A*STAR. Invitrocue and GIS will jointly conduct a pilot feasibility study using Invitrocue’s cell-based 3D scaffolding technology (Onco-PDO™) to culture colorectal cancer organoids. The aim of the study is to […]

Learn more
Published On 06 September

InvitroCue Awarded A*STAR Tender

September 05, 2016 – InvitroCue (ASX:IVQ) has been awarded a tender by the Institute of Bioengineering and Nanotechnology, Agency for Science, Technology and Research (A*STAR), to supply and deliver Hepatocue 96-well plates and 3D-Cellusponge 96-well plates. A*STAR will be utilizing InvitroCue’s technologies to advance research on non-animal approaches to chemical safety testing under an international […]

Learn more
Published On 22 August

InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou

August 22, 2016 – InvitroCue Limited (ASX:IVQ) has announced that its wholly owned subsidiary InvitroCue Biomedical Service Suzhou (“InvitroCue Suzhou”) has signed a Strategic Partnership Agreement with QIAGEN Suzhou Translational Medicine Co. Limited (“QIAGEN Suzhou”).   Pursuant to the agreement, InvitroCue Suzhou and QIAGEN Suzhou will jointly accelerate the discovery of biomarkers and translational medicine […]

Learn more
Published On 28 July

InvitroCue Announces New Program Focused on Hepatitis B Virus

July 28, 2016 – InvitroCue (ASX:IVQ), has signed a research collaboration program with Yong Loo Lin School of Medicine, National University of Singapore. The program will focus on InvitroCue’s “3D human liver” to model an in vitro system for the study of chronic Hepatitis B infection. If the program delivers promising data and results by […]

Learn more
Published On 11 July

InvitroCue Commences Pancreatic Toxicity Assay Development

11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. […]

Learn more
Published On 24 May

InvitroCue Announces Publication of Results in Human Stem Cell Derived Hepatocytes in 3D Culture System Used in Liver Drug Testing Assays

May 24, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced that the results of the Company’s 3D Culture System for growing stem cell derived hepatocytes have been published in the May print and web editions of Molecular Pharmaceutics (Mol. Pharmaceutics). Mol. Pharmaceutics is an official peer-reviewed online scientific journal which focuses […]

Learn more
Published On 20 May

InvitroCue Convenes Scientific and Medical Advisory Board

May 20, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced the appointment of leading experts to its newly formed Scientific and Medical Advisory Board (“SAB”). The SAB will guide the company in a broad range of activities including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging. “We are […]

Learn more
Published On 16 May

InvitroCue Announces Malaria Initiative

May 16, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today a key initiative on Malaria to identify and evaluate new drug targets to tropical infectious diseases. Following its successful initiative on leishmaniasis, InvitroCue establishes an open and collaborative strategy that involves integrated partnerships and networks between academic infectious diseases institutes and pharmaceutical […]

Learn more
Published On 12 May

InvitroCue Expands 3D Cell-based Platform for Oncology

May 12, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today that it is planning to enter the oncology testing market for drugs to provide data points in selected solid tumours. Using its revolutionary 3D cell-based technology and proprietary processes, InvitroCue will be able to culture patient derived cancer cells in its laboratories […]

Learn more
Published On 08 April

InvitroCue and SciKon Innovation Forge an Alliance to Create the Future of Perfused Human Liver Tissue

SINGAPORE and RESEARCH TRIANGLE PARK, NORTH CAROLINA USA April 08, 2016 – InvitroCue (ASX:IVQ), the in-vitro cell-based assaying company, and SciKon Innovation Inc. a US-based life sciences company,  today announce a strategic technology partnership that will enable InvitroCue to enhance its focus on delivering customer-centric innovation for its high-value biopharmaceutical customers. The agreement will allow […]

Learn more
Published On 08 April

InvitroCue Launches Cellacyl: Proprietary Acyl Glucuronide Detection Assay

SINGAPORE April 08, 2016 – InvitroCue (ASX:IVQ), the in vitro cell-based assaying company, today announce the global launch of its proprietary CellacylTM assay to monitor and screen carboxylated drug compounds for acyl glucuronides in liver-derived cells (hepatocytes), enabling pharmaceutical companies to streamline compound-ranking during the early phases of drug discovery. Cellacyl is a unique in […]

Learn more
Published On 09 March

Agreement with London School of Hygiene & Tropical Medicine

Download the InvitroCue Agreement PDF here: Agreement

Learn more
Published On 09 March

Novel 3D in vitro Techniques for Modeling leishmaniasis

09 March 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with London School of Hygiene & Tropical Medicine (London), recently signed an Agreement under which they started a collaboration using 3D in vitro technologies to establish leishmania spp. infection in vitro models. These technologies, when integrated, could offer a novel model for the in vitro […]

Learn more
Published On 05 March

InvitroCue Expands Cell-based Lab in Suzhou to Meet Client’s Increase China Focus

SINGAPORE and CHINA – March 05, 2016 – InvitroCue Pte Ltd and InvitroCue Biomedical Service Suzhou, a wholly owned subsidiary, today jointly announced the expansion of a cell-based laboratory facility in Suzhou to enhance the company’s current service offerings, and to meet current and future growth of the drug development in China. The expansion is […]

Learn more
Published On 01 February

ImageIQ And InvitroCue Forge Partnership To Advance Quantitative Image Analysis For Preclinical Researchers In Asia

CLEVELAND, OHIO and SINGAPORE – February 01, 2016 – ImageIQ, an innovative Imaging Software and Contract Research Organization supporting preclinical research and clinical trials, announced today an agreement with InvitroCue (“IVQ”), a Singapore-based provider of biomedical quantitative image analytic products and services, to enhance and accelerate preclinical research through the use of cloud-based image analysis […]

Learn more
Published On 28 January

NCCS And InvitroCue To Develop Quantitative Cancer Imaging And Radiomics Applications For Treatment Of Liver Cancer Patients

National Cancer Centre Singapore (NCCS) has signed a Memorandum of Understanding (MOU) with InvitroCue Pte Ltd (IVQ) to collaborate on research in the development of applications that will improve treatment outcomes in primary liver cancer or Hepatocellular Cacinoma (HCC). This translational and clinical research in Radiomics is an initiative that will move precision medicine into clinical […]

Learn more
Published On 08 April

InvitroCue and Swiss InSphero MOU Signing Ceremony

MOU Signing Ceremony between InvitroCue and Swiss InSphero and Technology Sharing Session On 8th April, 2015, the technology sharing session entitled “Cell Modeling and Analysis Method for Drug Research” was held at NUS (Suzhou) Research Institute. As one of the activities of Singapore-China (Suzhou) Innovation Centre’s NUSRI International Technology Commercialisation platform, the platform steadily supports […]

Learn more